On April 25, 2019, Qianhai Master Fund held the Henan Private Equity Investment Summit Forum and 2018 Annual Partner Conference, "Focusing on the Science Innovation Board and Cultivating New Kinetics", in Sofitel International Hotel, Zhengzhou. Bai Yi, General Manager of Dongfang Baitai, was invited to attend and won the Best Performance Award of the Best Investment Case Award.

Qianhai Equity Investment Fund (Limited Partnership) is referred to as "Qianhai Master Fund" for short. A large-scale commercial equity investment master fund set up in Shenzhen Qianhai in December 2015. The total scale is 28.5 billion yuan. It is currently the largest commercial fund-raising master fund and a leading private equity investment fund in China.

Beijing Dongfang Baitai Biotechnology Co., Ltd. is a leading enterprise in the field of biomedicine in China. The company was founded in 2011 and is located in Yizhuang Economic and Technological Development Zone. It is a high-tech enterprise engaged in the research, development and production of innovative antibody drugs. It mainly focuses on new products of major disease treatment and preventive biological medicine.

The company has built an industrial technology platform with world advanced level, focusing on original antibody drugs and new therapeutic vaccines, and running through the whole process of R&D and production. The product indications cover many high incidence diseases such as malignant tumor, diabetes, rheumatoid arthritis, psoriasis, hyperlipidemia, etc. The product categories include all human monoclonal antibody, humanized monoclonal antibody, bispecific antibody, antibody fusion protein, antibody coupling drug, therapeutic vaccine, etc. At present, 6 varieties have entered the clinical research stage, and 12 varieties are in different stages of pre clinical research and development.

Qianhai Equity Investment Fund invested in Dongfang Baitai in 2017. After nearly two years of growth, the company has continued to strengthen the development of innovative antibody drug technology, enrich the layout of R&D pipelines, improve the product echelon, accelerate the progress of clinical trials, and accelerate the completion of the construction of Dongfang Baitai Antibody Drug R&D and Production Base. Dongfang Baitai has stood out in many projects of Qianhai Equity Investment Fund and won the Best Performance Award of the Best Investment Case Award.

"Focusing on the Science and Technology Innovation Board and Cultivating New Kinetics" Henan Private Equity Investment Summit was co sponsored by Henan Development and Reform Commission, Henan Local Financial Supervision and Administration Bureau, Qianhai Master Fund and Zhongyuan Qianhai Equity Investment Fund. The guests who participated in the Summit Forum included Comrade Zhu Huanran, Secretary General of the People's Government of Henan Province, and the leaders of the Development and Reform Commission of Henan Province, the local financial supervision and administration bureau, and the securities regulatory bureau. At the same time, more than 300 people, including Qianhai Master Fund, investors of Zhongyuan Qianhai Equity Investment Fund, experts from the Shanghai Stock Exchange Registration and Audit Center, domestic well-known equity investment fund partners, outstanding entrepreneurs from 5G, medical health, intelligent manufacturing and other fields, industry experts, relevant investment and financing platforms of Henan provincial government and municipal governments, relevant financial institutions, listed companies, and heads of enterprises to be listed, participated in the activity.

At the forum meeting, Comrade Zhu Huanran, Secretary General of Henan Provincial Government, and Mr. Jin Haitao, Chief Executive Partner of Qianhai Master Fund delivered speeches respectively. Bai Yi, General Manager of Dongfang Baitai, as an expert of biomedical enterprises, was invited to participate in the round table forum of "Development Trends and Investment Opportunities of Medical and Health Industry". He discussed with many leaders, experts, investors, entrepreneurs and other guests in the medical and health industry about the development trend and investment opportunities of the medical and health industry.

Health is the eternal theme of mankind. In the past two years, under the background of intensive adjustment of industrial policies and drastic changes in the capital market, China's medical industry has also presented a new development trend. Since the 2017 medical insurance negotiation, after the test of the medical insurance negotiation and good sales data feedback, almost all pharmaceutical enterprises have realized that for most innovative drugs, the earlier they enter the medical insurance, the better. The adjustment of medical insurance catalogue in 2019 is imminent. Bai Yi, the general manager, shared with the participants the core issues that the enterprise needs to clarify, how to fully prove the value of the products, and what preparations the pharmaceutical enterprises need to make according to the industrial experience. At the same time, it discusses the impact of the newly issued 4+7 purchase policy on enterprises and the countermeasures that enterprises should take.

The participants interpreted and discussed the relevant new policies and regulations from the perspectives of policy, industry, terminal hospital and investment. We will jointly discuss the opportunities and challenges facing the industry, explore new ideas for the development of the industry, and help all parties to create a long-term common healthy ecosystem.

At the same time of the summit forum, the 2018 annual partner meeting of Qianhai Equity Investment Fund (Limited Partnership) was also held. The 2018 Annual Operation Report of Qianhai Equity Investment Fund (Limited Partnership) was reviewed at this partnership meeting. The Investment Briefing of Qianhai Equity Investment Fund (Limited Partnership) in the First Quarter of 2019 was reported. The Proposal on Establishing the Second Advisory Committee and Electing the Chairman of the Advisory Committee was reviewed.

At present, biotechnology drugs are the hotspot and key field of global drug research and development. Dongfang Baitai has taken root in the research and development of biological antibody drugs for many years. The company will continue to strengthen the development of innovative biotechnology drugs, and is committed to becoming a leading large pharmaceutical enterprise in China. In order to improve the market share and competitiveness of China's antibody drugs in the international advanced antibody drugs, and make unremitting efforts to establish a bio pharmaceutical innovative enterprise attracting global attention!